Search research articles
Contact Us
Filters
Showing results (481-490 of 564) with videos related to
Page
of 57
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2019
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Translational Oncology
|
November 15, 2020
Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology
Shaham Beg, Rohan Bareja, Kentaro Ohara, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 18, 2022
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma
Guru P Sonpavde, Cora N Sternberg, Yohann Loriot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2017
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Cell Reports. Medicine
|
February 14, 2023
Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer
Brittiny Dhital, Sandra Santasusagna, Perumalraja Kirthika, et al.
The Lancet. Oncology
|
November 13, 2012
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Christopher J Logothetis, Ethan Basch, Arturo Molina, et al.
The Lancet. Oncology
|
March 7, 2015
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
Daniel P Petrylak, Nicholas J Vogelzang, Nikolay Budnik, et al.
The Oncologist
|
August 6, 2021
Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease
Risa L Wong, Lorin A Ferris, Olivia A Do, et al.
The Lancet. Oncology
|
September 14, 2020
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study
Karim Fizazi, Gero Kramer, Jean-Christophe Eymard, et al.
The New England Journal of Medicine
|
February 18, 2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J Vaughn, et al.
Page
of 57
Search research articles
Search
Showing results (481-490 of 564) with videos related to
Sort By:
Page
of 57
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2019
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Translational Oncology
|
November 15, 2020
Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology
Shaham Beg, Rohan Bareja, Kentaro Ohara, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 18, 2022
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma
Guru P Sonpavde, Cora N Sternberg, Yohann Loriot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2017
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Cell Reports. Medicine
|
February 14, 2023
Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer
Brittiny Dhital, Sandra Santasusagna, Perumalraja Kirthika, et al.
The Lancet. Oncology
|
November 13, 2012
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Christopher J Logothetis, Ethan Basch, Arturo Molina, et al.
The Lancet. Oncology
|
March 7, 2015
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
Daniel P Petrylak, Nicholas J Vogelzang, Nikolay Budnik, et al.
The Oncologist
|
August 6, 2021
Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease
Risa L Wong, Lorin A Ferris, Olivia A Do, et al.
The Lancet. Oncology
|
September 14, 2020
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study
Karim Fizazi, Gero Kramer, Jean-Christophe Eymard, et al.
The New England Journal of Medicine
|
February 18, 2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J Vaughn, et al.
Page
of 57